This is a key analysis. No easy extrapolation from clinical trials to real life https://t.co/e5p8ZEvZrR
RT @RielyMD: Wow https://t.co/kefkEtFxSO
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @LindaMileshkin: Well done on an important paper to help us discuss immunotherapy outcomes with pts @anmwongNZ @Prof_G_McArthur https://…
RT @DrR_DUNNE: Important👇 we often quote old studies that pts with ECOG 3-4 have poorer outcomes w #chemo Now hv more direction when giving…
Well done on an important paper to help us discuss immunotherapy outcomes with pts @anmwongNZ @Prof_G_McArthur https://t.co/MJd9PvnJ9g
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
Well done @anmwongNZ https://t.co/3i4ieY9Y8V
RT @fischmd: Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.…
RT @DrR_DUNNE: Important👇 we often quote old studies that pts with ECOG 3-4 have poorer outcomes w #chemo Now hv more direction when giving…
True for most all malignancies...as someone said to me once...It's the Karnofsky, stupid! https://t.co/Bu4CV3IWcp
Important👇 we often quote old studies that pts with ECOG 3-4 have poorer outcomes w #chemo Now hv more direction when giving #Immunotherapy https://t.co/kkVYlKXgb2
Pts with poor baseline performance status w/lower survival and response to anti-PD1 drugs in #melanoma. @anmwongNZ https://t.co/XZvveYSDFv https://t.co/g2UsL4Ulvl
PD1 Rx if frail - not looking good: Pt survival after anti-PD1 for met melanoma. ECOG 0–1 cf ECOG 2–3 @anmwongNZ https://t.co/7wp5KslAHI https://t.co/A0GCNmMkjn
RT @anmwongNZ: Here's the link to the paper: https://t.co/Mo2KmBYC7z https://t.co/L01UKlslAp
Here's the link to the paper: https://t.co/Mo2KmBYC7z https://t.co/L01UKlslAp